AngioDynamics (FRA:UG2) Research & Development: €24.1 Mil (TTM As of Feb. 2026)


FRA:UG2 AngioDynamics Inc FRA:UG2
62 GF Score
Price €11.30
GF Value €7.27
! 7 Warning Signs
View Full Analysis

What is AngioDynamics Research & Development?

AngioDynamics FRA:UG2 +4.63% 62 Research & Development is €24.1 Mil as of Feb. 2026. GuruFocus rates FRA:UG2 with a GF Score™ of 62/100 and a GF Value™ of €7.27. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. AngioDynamics's Research & Development for the three months ended in Feb. 2026 was €6.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 was €24.1 Mil.

AngioDynamics  (FRA:UG2) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AngioDynamics Research & Development Related Terms

AngioDynamics Research & Development Historical Data

* Premium members only.

The historical data trend for AngioDynamics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics Research & Development Chart

AngioDynamics Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.95 29.08 27.49 29.15 23.26

AngioDynamics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.64 5.85 5.51 6.72 5.99
FRA:UG2
62GF Score
AngioDynamics Inc FRA:UG2
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AngioDynamics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €24.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €24.1 Mil mean?
AngioDynamics (FRA:UG2) has a Research & Development of €24.1 Mil as of Feb. 2026. Research and development expense is the total cost for research and development activities. View historical data on AngioDynamics and its competitors.
Is AngioDynamics' Research & Development too high?
AngioDynamics' current Research & Development is €24.1 Mil. Overall, AngioDynamics has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does AngioDynamics' Research & Development compare to OSUR and UTMD?
AngioDynamics' Research & Development of €24.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on AngioDynamics and its competitors. AngioDynamics's current Research & Development is €24.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AngioDynamics stock overvalued right now?
AngioDynamics (FRA:UG2) has a current Research & Development of €24.1 Mil. The stock's GF Value™ is €7.27, compared to a current price of €11.30 — trading 55.4% above its estimated fair value. The current Research & Development is €24.1 Mil. AngioDynamics' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For AngioDynamics (FRA:UG2), the current Research & Development is €24.1 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AngioDynamics (FRA:UG2) Overvalued in 2026?

Based on GuruFocus' analysis, AngioDynamics stock appears to be overvalued. The current stock price of €11.30 is trading 55.4% above its estimated GF Value™ of €7.27.

Key valuation signals for FRA:UG2:

  • Research & Development: €24.1 Mil
  • GF Value™: €7.27 vs. price of €11.30 (55.4% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the FRA:UG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AngioDynamics Business Description

Other Exchanges ANGO:USA
Address 14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
62GF Score

Get the complete analysis for FRA:UG2

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.30
Price
€7.27
GF Value